Evidence map›Paper›PMID 42180979›Full record

ArticleTranslational cancer research2026

PTTG1-DLX2 axis drives malignant progression of lung adenocarcinoma by activating the WNT/β-catenin signaling pathway.

Huili Chen, Xinyu Zhang, Xiaofu Lian, Ziqiang Wang, Feiyue Zhang, Jing Zhang, Shengping Min, Shasha Yang, Xiaojing Wang, Chaoqun Lian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Huili ChenResearch Center of Clinical Laboratory Science, Bengbu Medical University, Bengbu, China.
Xinyu ZhangResearch Center of Clinical Laboratory Science, Bengbu Medical University, Bengbu, China.
Xiaofu LianAnhui Province Key Laboratory of Immunology in Chronic Diseases, Bengbu Medical University, Bengbu, China.
Ziqiang WangAdvanced Medical Technology Center, Zhongshan School of Medicine and The First Affiliated Hospital, Sun Yat-sen University, Zhongshan, China.ORCID https://orcid.org/0009-0007-6928-1495
Feiyue ZhangDepartment of Genetics, School of Life Sciences, Bengbu Medical University, Bengbu, China.
Jing ZhangDepartment of Genetics, School of Life Sciences, Bengbu Medical University, Bengbu, China.
Shengping MinAnhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease, The Department of Pulmonary Critical Care Medicine, First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Shasha YangAnhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease, The Department of Pulmonary Critical Care Medicine, First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Xiaojing Wang *Anhui Province Key Laboratory of Clinical and Preclinical Research in Respiratory Disease, The Department of Pulmonary Critical Care Medicine, First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Chaoqun Lian *Research Center of Clinical Laboratory Science, Bengbu Medical University, Bengbu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality, and the molecular drivers that promote its malignant progression are not fully characterized. This study aimed to define the oncogenic function of pituitary tumor transforming gene 1 ( Methods: Results: PTTG1 was markedly upregulated in LUAD and associated with poorer patient survival. Higher Conclusions: This study identifies a PTTG1-DLX2-β-catenin signaling axis that drives LUAD malignant progression. These findings highlight

Indexed as

distal-less homeobox 2 (DLX2)Lung adenocarcinoma (LUAD)pituitary tumor transforming gene 1 (PTTG1)tumor metastasisWNT/β-catenin signaling pathway

Identifiers

PMID42180979
PMCPMC13190635

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.